Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta‐analysis

Yue Li, Xingkang He, Yue Ding, Hongyang Chen, Leimin SunCancer 2019 · DOI

TL;DR

This meta-analysis of 14 studies and over 130,000 patients provides strong evidence that statin use, both before and after a colorectal cancer (CRC) diagnosis, is associated with a significant reduction in both all-cause and cancer-specific mortality. These findings suggest statins may play a valuable role in improving outcomes for CRC patients.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a major global health challenge, ranking third in incidence and second in mortality. While the benefits of some drugs like aspirin in reducing CRC incidence and mortality are known, concerns about side effects and the need for alternative or complementary treatments persist. Statins, widely prescribed cholesterol-lowering drugs, have shown potential protective effects against cancer in preclinical studies. However, clinical evidence regarding their impact on CRC patient survival has been conflicting, leading to a lack of consensus on their prognostic role. This paper aims to systematically review and synthesize existing research to clarify the association between statin use and mortality in CRC patients.

Methods

The authors conducted a systematic review and meta-analysis, adhering to PRISMA guidelines. They searched multiple databases (PubMed, Cochrane Library, Web of Science, EMBASE, SCOPUS) for relevant studies published up to August 2017. Eligibility criteria included case-control or cohort studies investigating the association between statin use (pre- or post-diagnosis) and all-cause or cancer-specific mortality in CRC patients. Studies were assessed for methodological quality using the Newcastle-Ottawa Scale (NOS). Adjusted hazard ratios (HRs) were extracted and pooled using a random-effects model to calculate summary HRs with 95% confidence intervals (CIs). Subgroup analyses were performed to explore potential variations in the association based on factors like country, tumor site, stage, therapy, and KRAS mutation status.

Datasets

The study did not introduce new datasets. Instead, it analyzed data from 14 previously published studies. These studies included a total of 130,994 patients.

Key Insights and Ideas

  • Broad Applicability of Statins: The findings suggest that statins are beneficial regardless of whether they are used before a CRC diagnosis (potentially for prevention or early intervention) or after diagnosis (as an adjuvant therapy). This broad applicability is a significant insight.
  • Consistent Mortality Reduction: The consistent reduction in both all-cause and cancer-specific mortality across different study designs and patient populations strengthens the evidence for statins' positive impact.
  • Mechanistic Plausibility: The paper touches upon the underlying biological mechanisms by which statins might exert their anti-cancer effects, including suppressing tumor growth, inducing apoptosis, inhibiting angiogenesis, and potentially interfering with signaling pathways like EGFR via KRAS.
  • KRAS Mutation Status: While the study explored KRAS mutation status, it found no significant difference in all-cause mortality among post-diagnosis statin users based on KRAS mutation status. This suggests that statins' benefits might not be solely mediated through pathways directly targeted by KRAS mutations, or that the current data is insufficient to detect such a difference.

Key Results

  • Pre-diagnosis Statin Use:
    • All-cause mortality (ACM): Pooled HR of 0.85 (95% CI, 0.79-0.92).
  • Cancer-specific mortality (CSM): Pooled HR of 0.82 (95% CI, 0.79-0.86).
  • Post-diagnosis Statin Use:
    • All-cause mortality (ACM): Pooled HR of 0.86 (95% CI, 0.76-0.98).
  • Cancer-specific mortality (CSM): Pooled HR of 0.79 (95% CI, 0.70-0.89).
  • Heterogeneity: While some analyses showed considerable heterogeneity (e.g., post-diagnosis ACM with I² = 75.3%), the overall conclusions remained consistent.
  • Publication Bias: No evidence of publication bias was found in the analyses.

Limitations and Future Work

The authors acknowledge several limitations:

  • Heterogeneity: While subgroup analyses did not significantly alter results, other potential sources of heterogeneity (statin dose, duration, specific CRC location, pathological differentiation) were not fully explored due to data limitations.
  • Small Subgroup Sample Sizes: Some subgroup analyses, particularly those involving KRAS mutation status, had limited study numbers, potentially affecting the robustness of their conclusions.
  • Lack of Dose-Response Analysis: The study could not conduct a dose-response analysis due to insufficient data, which is a potential confounding factor.
  • Exclusion of DFS/RFS: Disease-free survival (DFS) and recurrence-free survival (RFS) were not included due to insufficient available evidence.

Future work should focus on:

  • Larger studies and RCTs to confirm these findings.
  • Further investigation into the role of statins in conjunction with targeted therapies, especially concerning KRAS mutations.
  • Exploring the impact of statin dose, duration, and specific types on CRC outcomes.
  • Investigating the effects of statins on DFS and RFS.

The authors conclude that while statins are low-cost and widely used, their prescription should not yet be a routine for CRC prevention or treatment without further clinical validation.

Summary updated

Abstract

Our meta-analysis demonstrates that both pre-diagnosis and post-diagnosis statin uses are associated with reduced ACM and CSM for CRC patients.
BibTeX
@inproceedings{li2019statin,
  author = {Yue Li and Xingkang He and Yue Ding and Hongyang Chen and Leimin Sun},
  title = {{Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta‐analysis}},
  booktitle = {Cancer},
  year = {2019},
  doi = {10.1002/cam4.2151},
}
Figure